journal article·2023-04-14

Cancer-Cell-Biomimetic Carbazole-Based AIE Nanoplatform for Targeted Phototheranostics of Lung Cancer

Huiqing Shen, Yue Li, Xiaoying Kang, Juan Wu, Ru Chen, Xiaolei Wei, Xinri Zhang, Ji Qi, Qian Liu

ACS Applied Nano Materials· Volume 6· Issue 7
Publisher page

Abstract

Lung cancer is one of the most diagnosed cancers and is the leading cause of cancer death. Photodynamic therapy (PDT) has been considered as a promising strategy due to its strong efficacy and negligible side effects. The development of potent PDT agents with an excellent tumor targeting capability is highly desirable but still not satisfied. In this work, we report a highly efficacious organic nanoplatform based on an aggregation-induced emission luminogen (AIEgen) and biomimetic modification for precise phototheranostics of lung cancer. An AIEgen with strong light absorption ability and bright deep red/near-infrared emission is designed and synthesized that possesses both type I and type II PDT processes. The AIEgen is encapsulated into nanoparticles (NPs) and further camouflaged with a Lewis lung carcinoma cell membrane to build a biomimetic nanoplatform. Both in vitro and in vivo experiments indicate that the cancer-cell-biomimetic NPs could significantly increase the tumor cell targeting ability and sensitively delineate the tumor site. Moreover, the cell-membrane-camouflaged NPs also show excellent antitumor efficacy in lung-cancer-bearing mice. This work demonstrates that the integration of highly efficient AIEgen and biomimetic cell membranes is able to boost the phototheranostic efficacy, representing a promising strategy for precise cancer diagnosis and treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Luminescence and Fluorescent Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

NHC Key Laboratory of Pneumoconiosis, Shanxi Key Laboratory of Respiratory, Department of Pulmonary and Critical Care Medicine, The First Hospital of Shanxi Medical University, The First Clinical Medical College of Shanxi Medical University, Taiyuan 030001, China

State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, Key Laboratory of Bioactive Materials, Ministry of Education, and College of Life Sciences, Nankai University, Tianjin 300071, China

Department of Urology, Tianjin First Central Hospital, Tianjin 300192, China

Funding

Chinese Academy of Medical Sciences · Central University Basic Research Fund of China · National Natural Science Foundation of China · Special Fund Project for Guiding Local Science and Technology Development by the Central Government

References (59)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1038/nrdp.2015.910.1038/nrdp.2015.9 ↗
3. 10.1016/S1470-2045(14)71180-510.1016/S1470-2045(14)71180-5 ↗
4. 10.1016/j.jpha.2022.12.00110.1016/j.jpha.2022.12.001 ↗
5. 10.1016/S0140-6736(16)30958-810.1016/S0140-6736(16)30958-8 ↗
6. 10.1038/s41572-020-00235-010.1038/s41572-020-00235-0 ↗
7. 10.1038/s41571-019-0173-910.1038/s41571-019-0173-9 ↗
8. 10.1038/s41591-021-01450-210.1038/s41591-021-01450-2 ↗
9. 10.1002/anie.20200110710.1002/anie.202001107 ↗
10. 10.1002/adfm.20190267310.1002/adfm.201902673 ↗
11. 10.1039/C9SC06441A10.1039/C9SC06441A ↗
12. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
13. 10.1021/acsanm.2c0180510.1021/acsanm.2c01805 ↗
14. 10.1002/anie.20201735010.1002/anie.202017350 ↗
15. 10.1039/D0CC04644B10.1039/D0CC04644B ↗
16. 10.1021/cr900236h10.1021/cr900236h ↗
17. 10.1016/j.biomaterials.2019.11958210.1016/j.biomaterials.2019.119582 ↗
18. 10.1002/anie.20220079910.1002/anie.202200799 ↗
19. 10.1021/jacs.0c0212910.1021/jacs.0c02129 ↗
20. 10.1038/s41467-022-29862-910.1038/s41467-022-29862-9 ↗
21. 10.1053/j.seminoncol.2014.09.01710.1053/j.seminoncol.2014.09.017 ↗
22. 10.1002/agt2.2510.1002/agt2.25 ↗
23. 10.1021/acsami.1c0766210.1021/acsami.1c07662 ↗
24. 10.1039/b105159h10.1039/b105159h ↗
25. 10.1021/acs.chemrev.5b0026310.1021/acs.chemrev.5b00263 ↗
26. 10.1021/acs.accounts.8b0006010.1021/acs.accounts.8b00060 ↗
27. 10.1002/adhm.20210106610.1002/adhm.202101066 ↗
28. 10.1021/acsanm.1c0086210.1021/acsanm.1c00862 ↗
29. 10.1002/anie.20191670410.1002/anie.201916704 ↗
30. 10.1039/D2SC00067A10.1039/D2SC00067A ↗
31. 10.1021/acsanm.2c0125010.1021/acsanm.2c01250 ↗
32. 10.1021/jacs.0c0243410.1021/jacs.0c02434 ↗
33. 10.1021/acsnano.1c1001910.1021/acsnano.1c10019 ↗
34. 10.1016/j.biomaterials.2020.12003610.1016/j.biomaterials.2020.120036 ↗
35. 10.1021/jacs.0c0719310.1021/jacs.0c07193 ↗
36. 10.1038/nbt.333010.1038/nbt.3330 ↗
37. 10.1186/s12951-019-0514-y10.1186/s12951-019-0514-y ↗
38. 10.1016/j.pharmthera.2021.10787110.1016/j.pharmthera.2021.107871 ↗
39. 10.1016/j.indcrop.2022.11598610.1016/j.indcrop.2022.115986 ↗
40. 10.1002/advs.20210256110.1002/advs.202102561 ↗
41. 10.1038/s41467-021-26052-x10.1038/s41467-021-26052-x ↗
42. 10.1002/smll.20220382510.1002/smll.202203825 ↗
43. 10.1038/s41368-021-00144-210.1038/s41368-021-00144-2 ↗
44. 10.1002/smll.20200648410.1002/smll.202006484 ↗
45. 10.1093/nsr/nwab03910.1093/nsr/nwab039 ↗
46. 10.1016/j.biomaterials.2019.11969910.1016/j.biomaterials.2019.119699 ↗
47. 10.1002/adma.20170675910.1002/adma.201706759 ↗
48. 10.1021/acsnano.7b0904110.1021/acsnano.7b09041 ↗
49. 10.1073/pnas.171426711410.1073/pnas.1714267114 ↗
50. 10.1016/j.actbio.2021.03.05610.1016/j.actbio.2021.03.056 ↗
51. 10.1002/adma.20210788310.1002/adma.202107883 ↗
52. 10.1002/anie.20190512910.1002/anie.201905129 ↗
53. 10.1016/j.ccr.2022.21475410.1016/j.ccr.2022.214754 ↗
54. 10.1002/adma.20220330910.1002/adma.202203309 ↗
55. 10.1002/adfm.20190936910.1002/adfm.201909369 ↗
56. 10.18632/oncotarget.2360710.18632/oncotarget.23607 ↗
57. 10.1002/advs.20200249910.1002/advs.202002499 ↗
58. 10.1016/j.biomaterials.2021.12125510.1016/j.biomaterials.2021.121255 ↗
59. 10.1039/D2TB00679K10.1039/D2TB00679K ↗